Clinical Trials Logo

Obesity clinical trials

View clinical trials related to Obesity.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT05295160 Enrolling by invitation - Obesity Clinical Trials

Fasting-Associated Immune-metabolic Remission of Diabetes

FAIR
Start date: September 25, 2020
Phase: N/A
Study type: Interventional

People with a body mass index above 28 kg/m² and an onset of type 2 diabetes within the last 4 years had a remission (HbA1c <6.5% without medication) of diabetes in over 80% upon weight loss of 15 kg. Longer duration of diabetes reduced the chance of remission. The investigators will test whether there is a difference in remission upon weight loss of 15 kg using formula low calorie diets between subjects with a diabetes duration of <4 years vs. >8 years and oral treatment as primary end points. The immune metabolic programming of circulating monocytes will be investigated in detail regarding trained innate immunity and the endocrine responses will be determined using meal challenge tests.

NCT ID: NCT05232786 Enrolling by invitation - Obesity Clinical Trials

Awareness, Care & Treatment In Obesity Management - An Observation in Switzerland

ACTION-CH
Start date: March 18, 2022
Phase:
Study type: Observational

ACTION Switzerland is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor. The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.

NCT ID: NCT05225337 Enrolling by invitation - Obesity Clinical Trials

Time Restricted Eating for the Treatment of Type 2 Diabetes

Start date: January 25, 2022
Phase: N/A
Study type: Interventional

Innovative lifestyle strategies to treat type 2 diabetes (T2DM) are critically needed. "Time restricted feeding" (TRF), and involves confining the period of food intake to 6-8 h per day. TRF allows individuals to self-select foods and eat ad libitum during a large part of the day, which greatly increases compliance to these protocols. Recent findings show that TRF is effective for weight loss and improved glycemic control in patients with prediabetes. However, no study to date has examined the effects of TRF in subjects with T2DM. The present study will be the first to compare the effect of TRF versus CR for weight management and improved glycemic control in individuals with obesity and T2DM. This study will compare the effects of these diet regimens during 12-weeks of weight loss, followed by 12-weeks of weight maintenance on: Specific aim 1: Body weight, energy restriction and dietary adherence Specific aim 2: HbA1c, insulin sensitivity, and metabolic risk factors Specific aim 3: T2DM remission, medication use, and occurrence of adverse events

NCT ID: NCT05215886 Enrolling by invitation - Clinical trials for Bariatric Surgery Candidate

Cognitive Impairment, Obesity, and the Effects of Bariatric Surgery

Start date: January 1, 2022
Phase:
Study type: Observational

Study is designed to screen psychological cognitive baseline and retention/improvement after weight loss surgery.

NCT ID: NCT05168072 Enrolling by invitation - Obesity Clinical Trials

Weight Loss Effects of M-health App in Obesity Multidisciplinary Outpatient Clinic

Start date: December 10, 2021
Phase: N/A
Study type: Interventional

This is a randomized, open, controlled, single-center trial to identify the weight loss effects of adding mobile health application in obesity multidisciplinary outpatient clinic.

NCT ID: NCT05162001 Enrolling by invitation - Obesity; Drug Clinical Trials

Body Weight Response With Disulfiram in Humans

Start date: November 21, 2021
Phase: Early Phase 1
Study type: Interventional

Overweight and obesity due to food that exceeds the requirements is an increasingly common global problem. Lifestyle intervention and anorectic drugs result in minimal weight loss, which tends to be easily regained. In addition, drugs tend to have too many side effects and have had to be withdrawn from management schemes and even from the market. Disulfiram (Antabuse®️) is approved by the Food and Drug Administration against chronic alcohol addiction. In a mouse study, disulfiram prevented body weight gain and negated the adverse impact of an obesogenic diet on insulin; used properly it is a safe drug. Carrying out a testing-concept study with disulfiram will allow the establishment of guidelines on clinical studies focused on its use as an adjunct in the reduction and control of body weight.

NCT ID: NCT05146154 Enrolling by invitation - Obesity Clinical Trials

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Start date: June 1, 2022
Phase: Phase 4
Study type: Interventional

This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.

NCT ID: NCT05144737 Enrolling by invitation - Obesity Clinical Trials

A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program

Start date: November 21, 2021
Phase: N/A
Study type: Interventional

A pilot study titled "A Virtual Cardiometabolic Health Program for African Immigrants (The Afro-DPP Program) will be conducted to address the cardiometabolic of community-dwelling African immigrants who have multiple cardiometabolic risk factors including hypertension, Type 2 Diabetes, high cholesterol, and overweight/obesity. The proposed study will recruit a total of 60 participants and will use a non-equivalent control group design to test the effectiveness of the intervention at two African churches in the Baltimore, Washington, D.C. area. The two churches will be randomly assigned to the intervention or delayed intervention group. At the end of a 6-month follow-up period, the control church will receive the intervention (delayed control group). All participants will receive a Bluetooth-enabled digital scale (Omron Model: BCM-500) that measures body composition including Body Weight, Body Fat percentage, Visceral Fat, Skeletal Muscle percentage, Resting Metabolism and Body Mass Index. A Bluetooth-enabled blood pressure monitor (Omron Model: BP7250) will also be distributed to all participants. All participants will download the Omron Connect app which will allow the participants to sync participants' blood pressure readings and body composition readings into the app. The research team will access these readings to monitor study outcomes and participants progress during the follow-up period.

NCT ID: NCT05141214 Enrolling by invitation - Diabetes Clinical Trials

Virtual Reality as a Dietary Education Adjunct for Pediatric Patients With Obesity

Start date: June 6, 2022
Phase: N/A
Study type: Interventional

Childhood obesity is a national crisis, effecting up to 1 in 5 of children in the US. In the Lucile Packard Children's Hospital Pediatric Weight Management Clinic, the investigators educate parents and caregivers about the importance of dietary modification. In addition to physician guidance, the investigators partner with registered dieticians to counsel families during an hour-long interview. However, traditional methods of education are limited by long-term recall. A typical person only recalls 2- 3% of didactic content after a period of 30 days.In order to improve recall and increase involvement of our pediatric patients in their own dietary modifications, the investigators propose a feasibility study investigating the effectiveness of Virtual Reality (VR) in changing dietary choices and improving recall.

NCT ID: NCT05104450 Enrolling by invitation - Obesity Clinical Trials

Pragmatic Obstructive Sleep Apnea Weight Loss Trial Assessing Effectiveness and Reach

POWER
Start date: April 4, 2022
Phase: N/A
Study type: Interventional

Prevalent obesity related conditions like obstructive sleep apnea (OSA) represent an important opportunity to improve population health. OSA reduces quality of life and is associated with greater risk for cardiovascular disease. Although obesity is the single greatest reversible risk factor for OSA, patients with OSA and obesity rarely receive weight loss care to reverse OSA and other serious comorbidities. Efficacy trials reinforce that time and resource intensive lifestyle-based weight loss programs improve weight and physiologic measures of OSA severity (apnea hypopnea index, AHI). However, there are barriers to translating these findings into meaningful gains for population health. To meet these challenges, the investigators propose a pragmatic trial of proactively offering a remote video-based and self-directed lifestyle-based weight loss intervention with remote coaching to patients with OSA. The investigators primary aim is to test the effectiveness of a proactively delivered and pragmatic lifestyle intervention to improve co-primary endpoints of sleep-related quality of life and weight among patients with OSA and obesity. Secondarily, the investigators will compare additional outcomes between groups: cardiovascular risk scores, sleep symptoms, and AHI. Finally, the investigators will also conduct an implementation process evaluation informed by the RE-AIM framework to identify barriers and facilitators to widespread implementation. The investigators will identify patients with OSA and obesity nationwide (n=696) in VA using data from the VA's Corporate Data Warehouse (CDW), and the investigators will contact potentially eligible patients. After confirming eligibility and consent, the investigators will randomly assign subjects to receive the study's lifestyle intervention or usual care alone. The study uses CDW to assess weight change, supplemented by self-report when necessary. Subjects will complete questionnaires at baseline at 3, 12 and 24 months after randomization. The lifestyle intervention in POWER focuses on gradual lifestyle behavior change aimed at improving eating habits and increasing physical activity. It encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.